Open AccessTemsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report
Author(s) -
José Miguel Jurado,
Irene Zarcos,
Mayte Delgado,
Isabel Blancas,
Marta Legerén,
José L. García-Puche
Publication year - 2013
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2013.1184
Subject(s) - temsirolimus , sunitinib , medicine , cancer , adverse effect , disease , oncogene , oncology , kidney cancer , metastasis , lung cancer , molecular medicine , cancer research , pi3k/akt/mtor pathway , discovery and development of mtor inhibitors , cell cycle , apoptosis , biology , biochemistry
During the last decade, we have been developing new therapeutic strategies for the treatment of renal cancer, based on knowledge derived from molecular biology. We report a case of long-term renal metastatic cancer progression despite therapy with sunitinib and interleukin, which are the most active drugs in renal cancer. Disease stabilization for 58 weeks was achieved upon sequential use of temsirolimus, following the occurrence of disease progression during angiogenic therapy. The patient demonstrated excellent tolerance without marked symptoms for 10 months. Hypothyroidism and mumps-related adverse events were present. The survival time from diagnosis to lung metastasis was 8 years. Thus, this case demonstrates promising therapeutic effects of the sequential use of tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors during different stages of the disease.